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Reply to the Editor:
We thank Dr Horstkotte for his comments
on our article comparing two heart valves
by means of reports from the literature. In
describing the limitations of such compar-
isons, he gives us another opportunity to
stress the main purpose of our report,
which was to point out precisely these lim-
itations.
Dr Horstkotte found four “shortcom-
ings” and agreed with three “messages” in
our article. The shortcomings were (1) in-
consistent use of linearized rates, (2) inclu-
sion violation, (3) inadequate reflection of
follow-up techniques, and (4) publication
bias.
We attempted to include only late
events in the linearized event rates. Most
reports used in our study considered late
events only, but some used both early and
late events and some were unclear on this
point. We tried to separate those that used
late events from those that used both and
attempted classify those that were unclear
from other clues in the published reports,
but we found this extremely difficult. We
finally decided to use the results as pub-
lished, and we specified this in the Clinical
Material section.
We selected only articles that claimed
to adhere to the American Association for
Thoracic Surgery and Society of Thoracic
Surgeons guidelines for reporting,1,2 as did
Horstkotte and colleagues’ 1993 article,3
which said, “Prosthetic valve related and
anticoagulant-related complications were
reported according to the current guidelines
for reporting morbidity and mortality after
valve replacement surgery.”1 In addition
they used another set of definitions that
included minor bleeding events, but we
used only the major bleeding events, as
recommended by the American Associa-
tion for Thoracic Surgery and Society of
Thoracic Surgeons.2 We did not include
their 1994 article4 in our analysis.
We agree that the completeness of re-
porting complications is directly related to
the follow-up strategy. We only selected
articles with at least 95% follow-up com-
pleteness, evaluated the results as a func-
tion of follow-up completeness, and em-
phasized this issue in the Discussion
section. However, there is no doubt a wide
variation in the use of the word complete. A
thorough evaluation of this variable should
include not just the quantitative (percent-
age) aspect but also a qualitative descrip-
tion of what is meant. Such meanings can
range, for example, from regular office vis-
its with the patient to a phone contact with
a widowed spouse long after the patient has
died.
We attempted to eliminate articles that
did not use universal anticoagulation. We
apparently missed the fact that in Baudet
and associates’ report5 65 patients with
aortic replacements and 10 with mitral re-
placements received aspirin and dipyrid-
amole only for 1 year, and had a higher
incidence of thrombosis and embolism, be-
cause the article itself presented combined
linearized rates. If this article had been
eliminated from our study, however, it
would have not changed the conclusions.
The term publication bias refers to the fact
that the publication of research studies is
nonrandom but depends on the nature and
direction of their findings, as described in
our Discussion section.
We agree completely with the three
“messages” that Dr Horstkotte took from
our article—the needs for (1) refined re-
porting of complications, including grading
of severity, (2) consecutive patients, and
(3) thorough follow-up techniques—and
we again thank him for emphasizing these
points. The purpose of our study was to
stress the limitations of data collection and
definitions, as well as to present refined
statistical methods of valve comparison
used to deal with variability. The short-
comings that Dr Horstkotte mentioned
were exactly what we studied and dis-
cussed in the article.
YingXing Wu, MD
Gary Grunkemeier, PhD
Providence Health System
Portland, Ore
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Safety of bronchoplastic resection
after induction therapy for lung
cancer
To the Editor:
We read with interest the article by Ohta
and colleagues1 concerning the impact of
induction treatment on patients who un-
derwent full sleeve resection. Ohta and
colleagues1 concluded that preoperative
therapy did not significantly affect postop-
erative outcome. The issue of the impact of
the neoadjuvant chemotherapy in patients
with lung cancer is today an object of de-
bate. It has been demonstrated that right
pneumonectomy after induction treatment
is associated with a high risk of postoper-
ative complications,2 and Rendina and col-
leagues3 showed that lung-sparing resec-
tion could reduce the rate of
pneumonectomy and could provide an al-
ternative to a pneumonectomy after induc-
tion treatment.
We published in 2002 our experience
with 27 patients who underwent induction
treatment before lung-sparing resection.4
We had similar results, demonstrating that
chemotherapy or chemoradiotherapy be-
fore surgery did not influence postoperative
outcome. In addition, in our experience
postoperative radiotherapy done for pa-
tients with N2 disease did not influence
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bronchial anastomosis in terms of late com-
plications. Finally, the completeness of re-
section after lung-sparing resection in term
of extension of mediastinal and hilar lymph
node dissection was comparable to that ob-
tained after pneumonectomy. At present,
our experience with lung-sparing technique
for lung cancer after induction treatment
consists of 58 patients operated on through
a period of 5 years, and it represent 54% of
all sleeve resections performed during the
same period (n  106). A vascular resec-
tion was associated in 35% of cases. The
overall postoperative morbidity rate and
mortality of patients who underwent sleeve
resection were 34% and 4.7%, respec-
tively. Table 1 reports the comparison be-
tween the two groups (induction treatment
vs no treatment).
This recent updated experience con-
firms our previous results and strongly sup-
ports the result of the article of Ohta and
colleagues.1 Bronchoplastic resection after
induction chemotherapy is a safe treatment
for locally advanced lung cancer, and it
should be done whenever it is possible in-
stead of pneumonectomy.
G. Veronesi, MD
M. E. Leon
L. Spaggiari, MD, PhD
Division of Thoracic Surgery
European Institute of Oncology
Milan, Italy
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Reply to the Editor:
My coauthors and I appreciate the com-
ments by Veronesi and colleagues from the
European Institute of Oncology. We find
their results1 to be consistent with ours,2
with their latest study reconfirming our
conclusion. They had excellent outcomes
with a sleeve resection after induction ther-
apy; however, the overall morbidity and
mortality resulting from a primary opera-
tion were 44% and 6%, respectively, which
were higher than those of Kutlu and Gold-
straw3 (12% and 2%, respectively), who
used the same continuous suture technique
for the bronchial anastomosis as did Vero-
nesi and colleagues.1 The somewhat high
morbidity rate in their control group may
have had an influence on the statistical
comparison analysis. Because surgical
complications had a correlation with the
extent of surgical resections,4 patients in
their study who underwent a primary oper-
ation have probably received a more radi-
cal dissection of the tumor and invaded
organs.
In our experience to date, the overall
surgical morbidity of 22 patients who re-
ceived preoperative induction therapy is
32% and that of 38 patients who underwent
a primary operation is 8%, and no postop-
erative deaths have occurred. Thus we be-
lieve that a sleeve resection is useful for
any patient with centrally located advanced
lung cancer in whom the anatomy is suit-
able for such a procedure. Further, we can
insist, and are supported by the results of
Veronesi and colleagues,2 that a sleeve re-
section is a safe alternative to pneumonec-
tomy, irrespective of preoperative treat-
ment.
Mitsunori Ohta, MDa
Noriyoshi Sawabata, MDb
Hajime Maeda, MDb
Hikaru Matsuda, MDa
Department of General Thoracic Surgerya
Graduate School of Medicine
Osaka University
Division of Surgeryb
Toneyama National Hospital
Osaka, Japan
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Lack of evidence for vitamin C as
acute vasodilator
To the Editor:
We read with interest the article by Drossos
and colleagues.1 They measured radial ar-
tery diameter before and after acute oral
administration of vitamin C (2 g) in two
separate studies. Study one was a compar-
ison in healthy subjects comparing non-
smokers with smokers; study two was dou-
ble-blind comparison with diltiazem.
The article raises several issues that we
believe require clarification by the authors.
First, the article does not contain any data
on the diameter measurements. This is im-
portant, because previous studies2,3 that
TABLE 1. Comparison of postoperative morbidity and mortality in patients un-
dergoing bronchial sleeve resection (induction treatment versus no treatment)
Overall
(n  106)
Induction
(n  56)
No induction
(n  50)
P valueNo. % No. % No. %
Perioperative morbidity
Minor complications 29 27.5 12 21.4 17 34 .15
Major complications 7 6.6 5 8.9 2 4 .44
Late morbidity 6 5.6 3 5.3 3 6 .99
Perioperative mortality 5 4.7 2 3.6 3 6 .66
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